Icon Plc (NASDAQ:ICLR) – Stock analysts at Jefferies Group dropped their Q4 2017 earnings per share estimates for shares of Icon in a research note issued on Tuesday. Jefferies Group analyst D. Windley now forecasts that the medical research company will post earnings of $1.41 per share for the quarter, down from their previous estimate of $1.42. Jefferies Group has a “Buy” rating and a $132.00 price objective on the stock. Jefferies Group also issued estimates for Icon’s Q1 2018 earnings at $1.40 EPS, Q2 2018 earnings at $1.47 EPS, Q3 2018 earnings at $1.57 EPS, Q4 2018 earnings at $1.64 EPS, FY2018 earnings at $6.07 EPS and FY2019 earnings at $6.72 EPS.
Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.32 by $0.03. The business had revenue of $440.30 million for the quarter, compared to analyst estimates of $438.09 million. Icon had a return on equity of 28.42% and a net margin of 16.37%. Icon’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.19 EPS.
Other equities research analysts have also issued research reports about the company. Zacks Investment Research lowered Icon from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Credit Suisse Group reiterated an “outperform” rating and issued a $120.00 price target (up previously from $105.00) on shares of Icon in a research report on Monday, October 16th. KeyCorp reiterated an “overweight” rating and issued a $125.00 price target (up previously from $115.00) on shares of Icon in a research report on Monday, November 13th. They noted that the move was a valuation call. SunTrust Banks reiterated a “buy” rating and issued a $138.00 price target on shares of Icon in a research report on Sunday, October 29th. Finally, ValuEngine upgraded Icon from a “hold” rating to a “buy” rating in a research report on Sunday, December 31st. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $121.82.
Shares of Icon (NASDAQ ICLR) opened at $113.27 on Thursday. The firm has a market capitalization of $6,211.78, a price-to-earnings ratio of 22.02, a P/E/G ratio of 1.63 and a beta of 0.56. Icon has a 52-week low of $76.46 and a 52-week high of $124.48. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. LVM Capital Management Ltd. MI acquired a new position in shares of Icon in the 4th quarter valued at about $5,886,000. Atlantic Trust Group LLC acquired a new position in shares of Icon in the 3rd quarter valued at about $9,515,000. Fieldpoint Private Securities LLC acquired a new position in shares of Icon in the 3rd quarter valued at about $330,000. Insight Capital Research & Management Inc. acquired a new position in shares of Icon in the 3rd quarter valued at about $1,359,000. Finally, Janney Montgomery Scott LLC lifted its stake in shares of Icon by 11.1% in the 3rd quarter. Janney Montgomery Scott LLC now owns 12,237 shares of the medical research company’s stock valued at $1,394,000 after purchasing an additional 1,222 shares during the period. Hedge funds and other institutional investors own 89.66% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/13/q4-2017-earnings-forecast-for-icon-plc-issued-by-jefferies-group-iclr.html.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.